Boston Scientific plans to acquire Relievant Medsystems, the company behind the Intracept intraosseous nerve ablation system.
The deal values Relievant Medsystems at $850 million, and additional payments are expected over the next three years, according to a Sept. 19 news release.
Intracept is a minimally invasive, implant-free outpatient procedure aimed to address lower back pain. Its efficacy is backed by clinical trials.
The acquisition is explected to close in the first half of 2024.